ストックスクリーナーアプリを入手
76.82
0.08%
0.06
アフターアワーズ：
76.82
Ionis Pharmaceuticals Inc (IONS) 最新ニュース
Polycythemia Vera Market: Rapid Increment Driven by Innovation by 2034 – DelveInsight | Protagonist Therapeutics, Italfarmaco, Imago BioSciences, Silence Therapeutics, Ionis Pharma, Perseus Proteomics - Barchart.com
Ionis to hold first quarter 2026 financial results webcast - The Joplin Globe
Ionis Pharmaceuticals Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Ionis Pharmaceuticals Inc at Leerink Global Healthcare Conference Transcript - GuruFocus
Ionis Pharmaceuticals Inc at BMO Capital Markets Growth & ESG Conference (Virtual) Transcript - GuruFocus
Oligonucleotides Market Research and Competitive Landscape Report 2026 Featuring Novartis, Astellas, Alnylam Pharmaceuticals, Ionis Pharmaceuticals - Yahoo Finance
(IONS) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Ionis Pharmaceuticals (IONS) Receives Outperform Rating with Ele - GuruFocus
Ionis Pharmaceuticals Inc : Raymond James Res - Moomoo
Winners Losers: Is Ionis Pharmaceuticals Inc a top pick in the sector2026 Market Outlook & Free AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Ionis Pharmaceuticals (IONS) Receives Updated Analyst Rating fro - GuruFocus
BofA Securities Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating - Moomoo
IONS Stock Price, Quote & Chart | IONIS PHARMACEUTICALS INC (NASDAQ:IONS) - ChartMill
Antisense Oligonucleotides Market 2026-2033 | US$ 5,286.96 - openPR.com
Will Ionis Pharmaceuticals Inc benefit from sector rotation2026 Price Targets & AI Enhanced Market Trend Forecasts - baoquankhu1.vn
Ionis Extends Donidalorsen Into Children: What the New HAE Trial Means for Investors - TipRanks
Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy - GlobeNewswire Inc.
Treasury Yields: Can Ionis Pharmaceuticals Inc outperform in the next rallyQuarterly Risk Review & Step-by-Step Trade Execution Guides - baoquankhu1.vn
Ionis outlines >$2B peak sales target for olezarsen as new launches and pipeline catalysts drive 2026 outlook - MSN
IONS Technical Analysis & Stock Price Forecast - Intellectia AI
IONS PE Ratio & Valuation, Is IONS Overvalued - Intellectia AI
IONS Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Ionis Pharmaceuticals repriced drug ahead of key FDA decision, signals push into larger market - MSN
Ionis Pharmaceuticals, Inc. $IONS Shares Acquired by SG Americas Securities LLC - MarketBeat
Retinitis Pigmentosa Market to Reach US$ 26.2 Billion by 2032 - openPR.com
Multiple System Atrophy Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Ionis Pharma, Biohaven Pharma, Lundbeck A/S, Alterity Therapeutics, Theravance Biopharma, Brain Neuro - Barchart.com
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Insider Sell Alert: Shannon Devers Sells Shares of Ionis Pharmac - gurufocus.com
Insider Sell Alert: Shannon Devers Sells Shares of Ionis Pharmaceuticals Inc (IONS) - gurufocus.com
Devers, Ionis Pharmaceuticals EVP, sells $458,613 in IONS stock By Investing.com - Investing.com Canada
Ionis Pharmaceuticals (NASDAQ:IONS) EVP Shannon Devers Sells 6,193 Shares - marketbeat.com
J. Safra Sarasin Holding AG Purchases New Position in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
ETF Watch: Can Ionis Pharmaceuticals Inc weather a recessionWeekly Trade Summary & Low Risk Investment Opportunities - baoquankhu1.vn
Charcot-Marie-Tooth (CMT) Disease Market Size to Reach US$ - openPR.com
Form 144 | Ionis Pharmaceuticals(IONS.US) Director Proposes to Sell 5.47 Million in Common Stocks - Moomoo
H.C. Wainwright reiterates Ionis Pharmaceuticals stock rating at buy By Investing.com - Investing.com Canada
Assenagon Asset Management S.A. Cuts Stake in Ionis Pharmaceuticals, Inc. $IONS - marketbeat.com
The Bull Case For Ionis Pharmaceuticals (IONS) Could Change Following FDA Priority Review For Zilganersen - Sahm
FDA Priority Review Puts Ionis Zilganersen At Center Of Rare-Disease Story - Yahoo Finance
Why Is Ionis Pharmaceuticals (IONS) Down 7.9% Since Last Earnings Report? - Yahoo Finance
Vanguard disaggregates holdings; reports 0 IONS shares (IONS) - Stock Titan
Analysts Offer Insights on Healthcare Companies: Beam Therapeutics (BEAM), KalVista Pharmaceuticals (KALV) and Ionis Pharmaceuticals (IONS) - The Globe and Mail
Is It Time To Reassess Ionis Pharmaceuticals (IONS) After Its Strong One Year Share Price Run? - Sahm
Analysts Offer Insights on Healthcare Companies: COMPASS Pathways (CMPS) and Ionis Pharmaceuticals (IONS) - The Globe and Mail
Ionis Cuts Tryngolza Price Ahead Of Big New Indication - insights.citeline.com
Ionis Pharmaceuticals Repriced Drug Ahead Of Key FDA Decision Signals Push Into Larger Market - Benzinga
Why Barclays Thinks Ionis Is Headed for a 45% Surge From $73 to $106 - Yahoo Finance
Ionis Pharmaceuticals (NASDAQ:IONS) Price Target Raised to $106.00 at Barclays - MarketBeat
Barclays Raises Price Target for Ionis Pharmaceuticals (IONS) to $106 | IONS Stock News - GuruFocus
Spinal Muscular Atrophy Pipeline 2026: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Genentech, Chugai Pharma, Cytokinetics, Ionis Pharma, Genzyme Corp - Barchart
What is HC Wainwright's Estimate for IONS FY2027 Earnings? - marketbeat.com
IONS: HC Wainwright & Co. Raises Price Target to $120 | IONS Sto - GuruFocus
DAVENPORT & Co LLC Purchases 155,334 Shares of Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Stifel raises Ionis Pharmaceuticals price target on drug pricing By Investing.com - Investing.com Australia
Wolfe Research reiterates Ionis stock rating on pricing strategy - uk.investing.com
2.69%
0.25%
大文字化:
|
ボリューム (24 時間):